{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:16:07Z","timestamp":1790813767608,"version":"4.1.0"},"posted":{"date-parts":[[2025,9,27]]},"group-title":"Public and Global Health","reference-count":34,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,1,26]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Incarceration is a leading driver of tuberculosis in Latin America. Active case-finding in prisons may reduce population-wide tuberculosis burden, but optimal strategies and cost-effectiveness remain uncertain.<\/jats:p>\n <\/jats:sec>\n \n Methods and findings<\/jats:title>\n Using dynamic transmission models calibrated to Brazil, Colombia, and Peru, we simulated annual or biannual (twice-yearly) prison-wide screening, alone or combined with entry and exit screening from 2026-2035. We evaluated four algorithms: 1) symptom screening, 2) chest X-ray with computer-aided detection (CXR-CAD), 3) symptoms and CXR-CAD (follow-up testing if either is positive) and 4) GeneXpert Ultra with pooled sputum. Individuals screening positive then received individual Xpert. We projected impacts on within-prison and population-level tuberculosis incidence in 2035, along with discounted costs (2023 USD) and disability-adjusted life years (DALYs). Model projections showed that combined entry, exit, and biannual screening with CXR-CAD was highly impactful and cost-effective across countries, reducing tuberculosis incidence by 62-87% in prisons and 18-28% population-wide. Compared to only biannual CXR-CAD (the next best strategy), the incremental cost per DALY averted of adding entry and exit screening was $2984 (Brazil), $2925 (Colombia), and $645 (Peru). Adding symptom screening to CXR-CAD marginally increased benefit and was only cost-effective in Peru\u2019s higher-incidence prisons. Biannual screening alone remained cost-effective at prison incidence levels well below national averages. In settings without CXR-CAD, pooled Xpert was an impactful, cost-effective alternative.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n These modeling results support immediate national-level adoption of prison-wide tuberculosis screening twice-yearly and at entry and exit. Screening should begin with available methods while building capacity for CXR-CAD, the most cost-effective algorithm.<\/jats:p>\n <\/jats:sec>\n \n AUTHOR SUMMARY<\/jats:title>\n \n Why was this study done?<\/jats:title>\n \n \n In Latin America, rising incarceration has fueled the tuberculosis epidemic, with extremely high infection rates among people deprived of liberty. These effects extend beyond prison walls, driving tuberculosis spread in outside communities.<\/jats:p>\n <\/jats:list-item>\n \n Interventions targeted to prisons may have an outsized impact on reducing tuberculosis in the broader population.<\/jats:p>\n <\/jats:list-item>\n \n The World Health Organization strongly recommends systematic screening for tuberculosis in prisons, but there is little evidence on how often to screen, which methods to use, and whether these approaches are cost-effective across different country contexts.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>\n \n What did the researchers do and find?<\/jats:title>\n \n \n We developed mathematical models using data from Brazil, Colombia, and Peru to simulate different prison-based tuberculosis screening strategies and project their health impacts and costs.<\/jats:p>\n <\/jats:list-item>\n \n We compared prison-wide screening once or twice a year, screening at prison entry or exit, and combinations of these approaches. We also compared different screening methods using symptoms, chest X-ray with computer-aided detection (CXR-CAD), or pooled molecular testing (GeneXpert Ultra).<\/jats:p>\n <\/jats:list-item>\n \n The models projected that combining entry, exit, and twice-yearly prison-wide screening with CXR-CAD would be highly impactful and cost-effective in all three countries. This strategy could substantially reduce tuberculosis in prisons and in the general population.<\/jats:p>\n <\/jats:list-item>\n \n Twice-yearly prison-wide screening remained cost-effective even in prisons with much lower tuberculosis rates than national averages.<\/jats:p>\n <\/jats:list-item>\n \n CXR-CAD was the optimal screening method, but pooled molecular testing was also impactful and cost-effective where CXR-CAD was not available.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>\n \n Implications of all the available evidence<\/jats:title>\n \n \n Systematic screening in prisons, twice-yearly and at entry and exit, is projected to be highly impactful and cost-effective across different settings in Latin America.<\/jats:p>\n <\/jats:list-item>\n \n These findings support urgent adoption of intensive prison-based tuberculosis screening throughout the region, starting with the best available diagnostic tools while investing in CXR-CAD.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:sec>\n <\/jats:sec>","DOI":"10.1101\/2025.09.25.25336625","type":"posted-content","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T06:10:25Z","timestamp":1759039825000},"source":"Crossref","is-referenced-by-count":4,"title":["Comparative impacts and cost-effectiveness of tuberculosis active case-finding strategies in prisons in Brazil, Colombia, and Peru: a mathematical modeling study"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7964-712X","authenticated-orcid":false,"given":"Yiran E","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Population Health, Stanford University, Stanford, California, USA"},{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Victor","family":"Bortolotto Bampi","sequence":"additional","affiliation":[{"name":"Federal University of Mato Grosso do Sul, Campo Grande, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan F","family":"Arthur","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argita D","family":"Salindri","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Busatto","sequence":"additional","affiliation":[{"name":"National Tuberculosis Program, Ministry of Health, Bras\u00edlia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Avedillo Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Pan American Health Organization, Communicable Diseases Prevention, Control and Elimination, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Maria","family":"Pelissari","sequence":"additional","affiliation":[{"name":"National Tuberculosis Program, Ministry of Health, Bras\u00edlia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Dockhorn Costa Johansen","sequence":"additional","affiliation":[{"name":"National Tuberculosis Program, Ministry of Health, Bras\u00edlia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Arana-Narvaez","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro Fernando","family":"Moreno Roca","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfredo Santos","family":"Sol\u00eds Tupes","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Mori Jiu","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Alfredo","family":"Moreno Roca","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika Albertina","family":"Abreg\u00fa Contreras","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina Antonieta","family":"Alarc\u00f3n Guizado","sequence":"additional","affiliation":[{"name":"Direcci\u00f3n de Prevenci\u00f3n y Control de la Tuberculosis, Ministerio de Salud, Lima, Per\u00fa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Trujillo Trujillo","sequence":"additional","affiliation":[{"name":"Ministerio de Salud y Protecci\u00f3n Social, Subdirecci\u00f3n de Enfermedades Transmisibles, Bogot\u00e1, Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belkys","family":"Marcelino","sequence":"additional","affiliation":[{"name":"Pan American Health Organization, Communicable Diseases Prevention, Control and Elimination, Washington, DC, USA"},{"name":"School of Public Health, Universidad Aut\u00f3noma de Santo Domingo, Santo Domingo, Dominican Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica Alonso","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Pan American Health Organization, Communicable Diseases Prevention, Control and Elimination, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra Cecilia","family":"C\u00f3rdova Ayllon","sequence":"additional","affiliation":[{"name":"Instituto Penitenci\u00e1rio Nacional, Lima, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moises A","family":"Huaman","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-5192","authenticated-orcid":false,"given":"Jeremy D","family":"Goldhaber-Fiebert","sequence":"additional","affiliation":[{"name":"Department of Health Policy, Stanford University School of Medicine, Stanford, California, USA"},{"name":"Center for Health Policy, Freeman Spogli Institute, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6665-6825","authenticated-orcid":false,"given":"Julio","family":"Croda","sequence":"additional","affiliation":[{"name":"Federal University of Mato Grosso do Sul, Campo Grande, Brazil"},{"name":"Department of Epidemiology of Microbial Diseases, School of Public Health, Yale University, New Haven, Connecticut, USA"},{"name":"Fiocruz Mato Grosso do Sul, Campo Grande, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R","family":"Andrews","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026020310450030000_2025.09.25.25336625v2.1","unstructured":"WHO. Global tuberculosis report 2024. 2024."},{"issue":"10284","key":"2026020310450030000_2025.09.25.25336625v2.2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/S0140-6736(20)32578-2","article-title":"The escalating tuberculosis crisis in central and South American prisons","volume":"397","year":"2021","journal-title":"The Lancet"},{"issue":"7","key":"2026020310450030000_2025.09.25.25336625v2.3","doi-asserted-by":"crossref","first-page":"e511","DOI":"10.1016\/S2468-2667(23)00097-X","article-title":"Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis","volume":"8","year":"2023","journal-title":"The Lancet Public Health"},{"issue":"11","key":"2026020310450030000_2025.09.25.25336625v2.4","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1016\/S2468-2667(24)00192-0","article-title":"Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study","volume":"9","year":"2024","journal-title":"The Lancet Public Health"},{"issue":"4","key":"2026020310450030000_2025.09.25.25336625v2.5","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1016\/S2468-2667(23)00002-6","article-title":"Scaling up evidence-based approaches to tuberculosis screening in prisons","volume":"8","year":"2023","journal-title":"The Lancet Public Health"},{"key":"2026020310450030000_2025.09.25.25336625v2.6","unstructured":"World Health Organization. WHO Consolidated Guidelines on Tuberculosis. Module 2: Screening - Systematic Screening for Tuberculosis Disease, 2021."},{"key":"2026020310450030000_2025.09.25.25336625v2.7","doi-asserted-by":"publisher","DOI":"10.1093\/CID\/CIAA135"},{"issue":"3","key":"2026020310450030000_2025.09.25.25336625v2.8","first-page":"564","article-title":"National Active Case-Finding Program for Tuberculosis in Prisons, Peru, 2024","volume":"31","year":"2025","journal-title":"Emerging Infectious Disease journal"},{"key":"2026020310450030000_2025.09.25.25336625v2.9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab847"},{"key":"2026020310450030000_2025.09.25.25336625v2.10","doi-asserted-by":"crossref","unstructured":"Salindri AD BJ , Busatto C , da Silva AM , da Silva Santos A , Gon\u00e7alves IB , Gon\u00e7alves TO , Cunha EAT , Tsuha D , Lemos E , Oliveira RD , Croda M , Andrews JR , Croda J. Evaluation of an ultra-portable X-ray system with automated interpretation for tuberculosis active case finding in carceral: a diagnostic test accuracy study settings . Research Square (PREPRINT) 2025.","DOI":"10.21203\/rs.3.rs-5578367\/v1"},{"key":"2026020310450030000_2025.09.25.25336625v2.11","unstructured":"Dara M , Chorgoliani D , de Colombani P . TB prevention and control care in prisons: World Health Organization\/Europe Health in Prisons Programme, 2014."},{"issue":"1","key":"2026020310450030000_2025.09.25.25336625v2.12","doi-asserted-by":"crossref","first-page":"e1002737","DOI":"10.1371\/journal.pmed.1002737","article-title":"Evaluating strategies for control of tuberculosis in prisons and prevention of spillover into communities: An observational and modeling study from Brazil","volume":"16","year":"2019","journal-title":"PLOS Medicine"},{"key":"2026020310450030000_2025.09.25.25336625v2.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002100"},{"issue":"12","key":"2026020310450030000_2025.09.25.25336625v2.14","doi-asserted-by":"crossref","first-page":"e1679","DOI":"10.1016\/S2214-109X(21)00367-3","article-title":"Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae","volume":"9","year":"2021","journal-title":"The Lancet Global Health"},{"key":"2026020310450030000_2025.09.25.25336625v2.15","unstructured":"World Bank. GDP deflator (base year varies by country). 2023."},{"key":"2026020310450030000_2025.09.25.25336625v2.16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"2026020310450030000_2025.09.25.25336625v2.17","unstructured":"Ministerio de Salud DGdM , Insumos y Drogas ,. Estimaci\u00f3n del umbral costo - efectividad para las evaluaciones econ\u00f3micas en salud. Informe t\u00e9cnico. Per\u00fa, 2022."},{"key":"2026020310450030000_2025.09.25.25336625v2.18","unstructured":"Minist\u00e9rio da Sa\u00fade . O uso de limiares de custo-efetividade nas decis\u00f5es em sa\u00fade: recomenda\u00e7\u00f5es da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS. In: Secretaria de Ci\u00eancia T , Inova\u00e7\u00e3o e Insumos Estrat\u00e9gicos em Sa\u00fade ; Departamento de Gest\u00e3o e Incorpora\u00e7\u00e3o de Tecnologias em Sa\u00fade, editor. Brasilia\/DF, Brazil; 2022."},{"issue":"3","key":"2026020310450030000_2025.09.25.25336625v2.19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/heapol\/czab146","article-title":"Estimating cost-effectiveness thresholds under a managed healthcare system: experiences from Colombia","volume":"37","year":"2022","journal-title":"Health Policy and Planning"},{"key":"2026020310450030000_2025.09.25.25336625v2.20","doi-asserted-by":"crossref","unstructured":"Soares TR , Oliveira RDd , Liu YE , et al. Evaluation of chest X-ray with automated interpretation algorithms for mass tuberculosis screening in prisons: a cross-sectional study. The Lancet Regional Health - Americas 2023; 17: 100388.","DOI":"10.1016\/j.lana.2022.100388"},{"key":"2026020310450030000_2025.09.25.25336625v2.21","doi-asserted-by":"publisher","DOI":"10.5588\/pha.18.0098"},{"issue":"1","key":"2026020310450030000_2025.09.25.25336625v2.22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2471\/BLT.16.169383","article-title":"Cost\u2013effectiveness of screening for active cases of tuberculosis in Flanders, Belgium","volume":"95","year":"2017","journal-title":"Bulletin of the World Health Organization"},{"key":"2026020310450030000_2025.09.25.25336625v2.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001348"},{"key":"2026020310450030000_2025.09.25.25336625v2.24","unstructured":"Sequera G , Estigarribia-Sanabria G , Aguirre S , et al. Excess tuberculosis risk during and following incarceration in Paraguay: a retrospective cohort study. The Lancet Regional Health \u2013 Americas."},{"issue":"4","key":"2026020310450030000_2025.09.25.25336625v2.25","first-page":"739","volume":"93","year":"2015","journal-title":"The Impact of Ventilation and Early Diagnosis on Tuberculosis Transmission in Brazilian Prisons. Am J Trop Med Hyg"},{"key":"2026020310450030000_2025.09.25.25336625v2.26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004288"},{"key":"2026020310450030000_2025.09.25.25336625v2.27","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-014-0204-1"},{"issue":"6","key":"2026020310450030000_2025.09.25.25336625v2.28","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/cid\/ciae055","article-title":"Serial Mass Screening for Tuberculosis Among Incarcerated Persons in Brazil","volume":"78","year":"2024","journal-title":". Clin Infect Dis"},{"key":"2026020310450030000_2025.09.25.25336625v2.29","doi-asserted-by":"publisher","DOI":"10.5588\/IJTLD.17.0526"},{"key":"2026020310450030000_2025.09.25.25336625v2.30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087262"},{"key":"2026020310450030000_2025.09.25.25336625v2.31","doi-asserted-by":"crossref","unstructured":"van\u2019t Hoog A , Viney K , Biermann O , Yang B , Leeflang MMG , Langendam MW. Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status. Cochrane Database of Systematic Reviews 2022; (3).","DOI":"10.1002\/14651858.CD010890.pub2"},{"key":"2026020310450030000_2025.09.25.25336625v2.32","doi-asserted-by":"crossref","unstructured":"dos Santos PCP , da Silva Santos A , de Oliveira RD , et al. Pooling Sputum Samples for Efficient Mass Tuberculosis Screening in Prisons. Clinical Infectious Diseases 2021.","DOI":"10.1093\/cid\/ciab847"},{"key":"2026020310450030000_2025.09.25.25336625v2.33","doi-asserted-by":"crossref","unstructured":"Shapiro AE , Ross JM , Yao M , et al. Xpert MTB\/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane Database of Systematic Reviews 2021; (3).","DOI":"10.1002\/14651858.CD013694.pub2"},{"key":"2026020310450030000_2025.09.25.25336625v2.34","doi-asserted-by":"crossref","unstructured":"Zifodya JS , Kreniske JS , Schiller I , et al. Xpert Ultra versus Xpert MTB\/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2021; (2).","DOI":"10.1002\/14651858.CD009593.pub5"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.09.25.25336625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:45:10Z","timestamp":1770144310000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.09.25.25336625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1101\/2025.09.25.25336625","relation":{},"subject":[],"published":{"date-parts":[[2025,9,27]]},"subtype":"preprint"}}